AstraZeneca/Sanofi’s Nirsevimab Nears US FDA Approval After Overwhelmingly Positive Adcomm

 
• By Derrick Gingery

When patients should receive the RSV prevention treatment was the subject of much debate even as the Antimicrobial Drugs Advisory Committee voted nearly unanimously that it should be approved for infants and neonates.

FDA AMDAC meeting screenshot
Advisory committee members voted that the benefits outweigh the risks of the proposed RSV prevention treatment nirsevimab. • Source: Screenshot

More from US FDA Performance Tracker

More from Regulatory Trackers